The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Randomized Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen Sodium (Bcl-2 antisense) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Abstract
Purpose: Expression of Bcl-2 protein is associated with chemotherapy resistance and decreased survival in chronic lymphocytic leukemia (CLL). We evaluated whether oblimersen would improve response to chemotherapy in patients with relapsed or refractory CLL. Patients and Methods: Patients had received at least one prior fludarabine-containing regimen and were stratified on the basis of prior fludarabine response, number of prior regimens, and duration of response to last prior therapy. Patients were randomly assigned to 28-day cycles of fludarabine 25 mg/m 2/d plus cyclophosphamide 250 mg/m 2/d administered intravenously for 3 days with or without oblimersen 3 mg/kg/d as a 7-day continuous intravenous infusion (beginning 4 days before chemotherapy) for up to six cycles. The primary end point was the proportion of patients who achieved complete response (CR) or nodular partial response (nPR). Results: Of 241 patients randomly assigned, CR/nPR was achieved in 20 (17%) of 120 patients in the oblimersen group and eight (7%) of 121 patients in the chemotherapy-only group (P = .025). Achievement of CR/nPR was correlated with both an extended time to progression and survival (P < .0001). In patients who remained sensitive to fludarabine, oblimersen was associated with a four-fold increase in the CR/nPR rate and a significant survival benefit (P = .05). Oblimersen was frequently associated with thrombocytopenia and, rarely, tumor lysis syndrome and cytokine release reactions; the incidence of opportunistic infections and second malignancies was similar in both groups. Conclusion: The addition of oblimersen to fludarabine plus cyclophosphamide significantly increases the CR/nPR rate in patients with relapsed or refractory CLL (particularly fludarabine-sensitive patients), as well as response duration among patients who achieve CR/nPR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., et al. (1999) · Blood · doi:10.1182/blood.v94.6.1840 · Cited by 2,642
Self-citationCheson, B., Bennett, J., Grever, M., Kay, N., Keating, M., O'Brien, S., & Rai, K. (1996) · Blood · doi:10.1182/blood.v87.12.4990.bloodjournal87124990 · Cited by 1,819
Self-citationCrespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., & Montserrat, E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa023143 · Cited by 1,055
Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.051 · Cited by 950
Self-citationRassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040857 · Cited by 745
Self-citationbcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia
Hanada, M., Delia, D., Aiello, A., Stadtmauer, E., & Reed, J. (1993) · Blood · doi:10.1182/blood.v82.6.1820.1820 · Cited by 673
Eichhorst, B. F. (2005) · Blood · doi:10.1182/blood-2005-06-2395 · Cited by 588
Byrd, J. C. (2003) · Blood · doi:10.1182/blood-2002-04-1258 · Cited by 571
Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.-A., Cortes, J., Koller, C., Beran, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.516 · Cited by 524
Self-citationCD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia
Ibrahim, S., Keating, M., Do, K.-A., O'Brien, S., Huh, Y. O., Jilani, I., Lerner, S., Kantarjian, H. M., & Albitar, M. (2001) · Blood · doi:10.1182/blood.v98.1.181 · Cited by 453
Self-citationResults of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia
O’Brien, S. M., Kantarjian, H. M., Cortes, J., Beran, M., Koller, C. A., Giles, F. J., Lerner, S., & Keating, M. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1414 · Cited by 347
Self-citationRobertson, L. E., Plunkett, W. K., McConnell, K., Keating, M. J., & McDonnell, T. J. (1996) · PubMed · Cited by 281
Oblimersen Bcl-2 Antisense: Facilitating Apoptosis in Anticancer Treatment
Klasa, R. J., Gillum, A. M., Klem, R. E., & Frankel, S. R. (2002) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729002760220798 · Cited by 280
Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
Schena, M., Larsson, L., Gottardi, D., Gaidano, G., Carlsson, M., Nilsson, K., & Caligaris- Cappio, F. (1992) · Blood · doi:10.1182/blood.v79.11.2981.2981 · Cited by 208
O'Brien, S. M., Cunningham, C. C., Golenkov, A. K., Turkina, A. G., Novick, S. C., & Rai, K. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.4364 · Cited by 194
Self-citationGenomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance.
Calin, G., & Croce, C. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.01.010 · Cited by 163
Reed, J. C., Kitada, S., Takayama, S.-I. J., & Miyashita, T. (1994) · Annals of Oncology · doi:10.1093/annonc/5.suppl_1.s61 · Cited by 149
Faderl, S. H., Keating, M. J., Do, K.-A., Liang, S.-Y., Kantarjian, H., O'Brien, S. M., García-Manero, G., Manshouri, T., & Albitar, M. X. (2002) · Leukemia · doi:10.1038/sj.leu.2402540 · Cited by 130
Self-citationThe clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia
Hus, I., Podhorecka, M., Bojarska-Junak, A. A., Roliński, J., Schmitt, M. W., Sieklucka, M., Wąsik‐Szczepanek, E., & Dmoszyńska, A. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj120 · Cited by 104
Chiu, S.-J., Liu, S., Perrotti, D., et al. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.02.011 · Cited by 96
Jahrsdörfer, B., Jox, R. J., Mühlenhoff, L., Tschoep, K., Krug, A., Rothenfußer, S., Meinhardt, G., Emmerich, B., Endres, S., & Hartmann, G. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.83 · Cited by 69
Human Bcl-2 antisense therapy for lymphomas
Cotter, F. E., Waters, J. S., & Cunningham, D. (1999) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00139-6 · Cited by 61
Dai, G., Chan, K. K., Liu, S., Hoyt, D. G., Whitman, S. P., Klisovic, M. I., Shen, T., Caligiuri, M. A., Byrd, J. C., Grever, M. R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1505 · Cited by 42
Oligonucleotides as modulators of cancer gene expression
Curcio, L. D., Bouffard, D. Y., & Scanlon, K. J. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00005-3 · Cited by 31
Novel murine B‐cell lymphoma/leukemia model to study BCL2‐driven oncogenesis
Meijerink, J. P. P., Lieshout, E. M. M. V., Beverloo, H. B., van Drunen, E., Mensink, E. J. B. M., Macville, M. V. E., & Pieters, R. (2005) · International Journal of Cancer · doi:10.1002/ijc.20822 · Cited by 21
Castro, J. E., Prada, C. E., Aguillon, R. A., Kitada, S., Fukuda, T., Motta, M., Wu, C. C. N., Dicker, F., Sun, G., Wang, J. Y. J., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404144 · Cited by 21
Branford, S., Rudzki, Z., Grigg, A., Seymour, J. F., Taylor, K. M., Browett, P., Schwarer, A. P., Bradstock, K. F., Arthur, C. K., Durrant, S., et al. (2004) · Blood · doi:10.1182/blood.v104.11.274.274 · Cited by 13
Self-citation
Cited by
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
MicroRNAs and other non-coding RNAs as targets for anticancer drug development
Ling, H., Fabbri, M., & Calin, G. A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4140 · Cited by 1,465
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,016
Bcl-2 family proteins and cancer
Yip, K. W., & Reed, J. C. (2008) · Oncogene · doi:10.1038/onc.2008.307 · Cited by 881
Metadata
- Authors
- O'Brien, S., Moore, J. O., Boyd, T. E., Larratt, L. M., Skotnicki, A., Koziner, B., Chanan-Khan, A. A., Seymour, J. F., Bociek, R. G., Pavletic, S., & Rai, K. R.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-03-20
- Volume
- 25
- Issue
- 9
- Pages
- 1114-1120
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2135551958
- Cited by
- 303
- References
- 28
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.